The company's low growth and lack of profits have led to a stock price drop. A revenue growth acceleration might boost the share price. However, the real benefit for shareholders will be if the company starts making profits. Despite recent gains, the returns over the last three years have been disappointing.
DENTSPLY SIRONA's decreasing capital employment and flat returns are concerning. The stock's decline may reflect investor pessimism about these trends. The analysis does not see the traits of a multi-bagger in this stock.
Investors predict limited future growth for the company, reflected by its low P/S ratio. The pessimism around its revenue prospect contributes to its undervalued stock.
DENTSPLY SIRONA, currently undervalued with steady price trends, could make a solid investment. Despite modest growth projections, aspects like capital structure and management track record could be behind its undervaluation.
The reversal of DENTSPLY SIRONA's stock downward trend might hinge on its profitability. Accelerated revenue growth could yield share price bounce. However, present indications show a 4% annual shareholder loss over five years.
There is concern over the falling ROCE and constant capital utilization, pointing towards a likely state of stagnation for the business. Unless there is an improvement in these areas, this stock might not be the best investment option.
Dentsply Sirona Stock Forum
In reaction to earnings/guidance:
• $CalAmp (CAMP.US)$ +0.6%
Other news:
• $Cano Health (CANO.US)$ +6.1% ( $Humana (HUM.US)$ in the running to acquire CANO according to WSJ)
• $Corcept Therapeutics (CORT.US)$ +4.5% (extends deal with Optime Care to March 31 2024)
• $LPL Financial (LPLA.US)$ +4.1% (reports monthly activity for August)
• $Dentsply Sirona (XRAY.US)$ +3% (names new CFO)
• $iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX.US)$ +2.9% (tr...
• $Repare Therapeutics (RPTX.US)$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $Chewy (CHWY.US)$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $UiPath (PATH.US)$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $Pure Storage (PSTG.US)$ +10.6% (In reaction to earnings)
• $Credo Technology (CRDO.US)$ +10.2% (In reaction ...
• $Agree Realty Corp (ADC.US)$: BofA Securities Upgrades Agree Realty (ADC) to Buy
• $Americold Realty Trust (COLD.US)$: BofA Securities Upgrades to Neutral from Underperform - PT $30 (from $28)
• $Ecolab (ECL.US)$: UBS Upgrades to Buy from Neutral - PT $205 (from $186)
• $Reinsurance Group of America (RGA.US)$: Credit Suisse Upgrades to Neutral from Underperform - PT $122 (from $80)
• $SolarEdge Technologies (SEDG.US)$: Oppenheimer Upgrades to Out...
No comment yet